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Rebeccamycin derivative 1 bearing a sugar moiety linked to both indole nitrogens and an amino 
substituent on the carbohydrate unit was synthesized in three steps from the bacterial metabolite. This 
compound was found to be a highly potent checkpoint kinase 1 inhibitor with an IC50 value of 2.8 nM. 
 




Rebeccamycin is a microbial metabolite isolated from cultures of Saccharothrix aerocolonigenes [1]. Its 
antiproliferative activity was shown to be linked to its capacity to inhibit topoisomerase I [2] and [3]. 
Topoisomerase I is a ubiquitous enzyme necessary for DNA replication and transcription. This nuclear 
enzyme catalyses DNA unwinding by cleaving one strand of the DNA, allowing the other strand to pass 
through the break and resealing the cleaved strand. Rebeccamycin, like camptothecins, is a topoisomerase 
I poison which stabilizes the “cleavable complex” and prevents the religation of the cleaved strand [4] 
and [5]. Rebeccamycin possesses a maleimide indolocarbazole framework onto which is attached a 4-O-
methyl glucopyranose via a β-N-glycosidic bond. Structure–activity relationship studies have been 
performed and several families of rebeccamycin analogues were prepared either by semi-synthesis or by 
total synthesis [2], [6], [7], [8], [9], [10], [11] and [12]. Among these families, a series of staurosporine 
analogues were obtained from rebeccamycin by semi-synthesis [13] and [14]. Staurosporine is a 
microbial metabolite, structurally related to rebeccamycin (Fig. 1).  
 
 
Fig. 1. Bacterial metabolites rebeccamycin and staurosporin, and rebeccamycin derivative 1. 
 
Both compounds possess an indolocarbazole chromophore but the main differences are the function in the 
upper heterocycle, lactam in staurosporine and imide in rebeccamycin, and the sugar moiety linked to 
both indole nitrogens in staurosporine and to only one indole nitrogen in rebeccamycin. Moreover the 
sugar part of staurosporine bears an amino substituent [15]. In contrast with rebeccamycin, staurosporine 
is not a topoisomerase I inhibitor but exhibits a non-selective inhibitory activity toward kinases including 
checkpoint kinase 1 (Chk1), a kinase involved in the regulation of the G2 cell cycle checkpoint [15], [16] 
and [17]. Among the staurosporine analogues obtained from rebeccamycin, compound 1 was especially 
interesting because of its amino substituent on the carbohydrate moiety that could mimic the one of 
staurosporine. Therefore, compound 1 was prepared by semi-synthesis from rebeccamycin but the first 
synthetic pathway required more than six steps [14]. In this paper, we report a three-step semi-synthesis 
of compound 1 from rebeccamycin. The inhibitory activity of compound 1 toward Chk1 and tyrosine 
kinase Src was determined. 
 
2. Chemistry 
In a previous work [14], we investigated the synthesis of compound 1 in six steps as shown in Scheme 1, 
the last step would be the reduction of azide 8 to the corresponding amine. Monotosylation was 
performed at the 2′ position of the carbohydrate, then reaction with sodium azide led to cyclized 
compound 3 as the major product. Dechlorination using ammonium formate in the presence of Pd/C gave 
compound 5. Chlorination at the 6′ position was carried out using CCl4 and PPh3 in pyridine but the 
required compound 6 was obtained as the minor product of the reaction in only 23% yield. Treatment of 
compound 6 with sodium azide led to azide 8 in 38% yield, but as in the case of the preparation of 
compound 6, the major product of the reaction was anhydro 7. The overall yield in the synthesis of azide 
8 from rebeccamycin was about 2%. 
 
Scheme 1. First attempt for the synthesis of compound 1 from rebeccamycin. 
To avoid the formation of by-products in steps 4 and 5 which lowered the overall yield, selective 
protection–deprotection sequence on the sugar moiety was investigated (Scheme 2) [14]. The hydroxy 
groups of the carbohydrate were protected as acetates, then a selective deprotection at the 6′ position was 
carried out using BF3–etherate in wet acetonitrile. Chlorination and nucleophilic substitution with sodium 
azide were performed as in the first synthesis. Reduction of the azide was then carried out by catalytic 
hydrogenation. Deprotection of the hydroxy group at the 3′ position was performed by aminolysis and the 
amine transformed into hydrochloride 1. In this second way, the overall yield for the synthesis of 1 was 
less than 2%, and the synthesis needed nine steps. 
 
 
Scheme 2. Synthesis of compound 1 in nine steps from rebeccamycin. 
 
In this paper, a three-step synthesis of compound 1 from rebeccamycin is reported. Ditosylated compound 
13 was obtained in 35% yield by reaction of rebeccamycin with 5 equiv. of tosyl chloride and K2CO3. By 
the treatment of 13 with sodium azide (20 equiv.) both nucleophilic substitution at the 6′ position and at 
the 2′ position occurred to give compound 14 in 53% yield. Reduction of the azide and dechlorination 
occurred simultaneously on treatment with ammonium formate and Pd/C. Hydrochloride 1 was obtained 
from 14 in 36% yield. The overall yield from rebeccamycin was improved (about 7%) and the synthesis 
needed only three steps (Scheme 3). 
 
Scheme 3. Three-step synthesis of compound 1 from rebeccamycin. 
3. Kinase inhibitory activities 
The Chk1 inhibitory activity of compound 1 was evaluated. The percentage of Chk1 inhibition at a drug 
concentration of 0.1 µM was 90%. The IC50 value toward Chk1 was found to be 2.8 nM. To get an insight 
into the kinase selectivity, the inhibitory activity of compound 1 was evaluated toward the Src tyrosine 
kinase. The percentage of Src inhibition at a drug concentration of 1 µM was 35%, much less than that 
toward Chk1. 
4. Conclusion 
In summary, a new synthesis of a staurosporine analogue, with the sugar unit linked to both indole 
nitrogens and bearing an amino function at the 6′ position on the carbohydrate moiety, was performed in 
three steps from rebeccamycin. This rebeccamycin derivative is especially interesting as a highly potent 
Chk1 inhibitor, with an IC50 value in the nanomolar range. 
5. Experimental 
5.1. Chemistry 
IR spectra were recorded on a Perkin–Elmer 881 spectrometer (  in cm−1). NMR spectra were performed 
on a Bruker AVANCE 400 and AVANCE 500 (chemical shifts δ in ppm, the following abbreviations are 
used: singlet (s), broad signal (br s), doublet (d), doubled doublet (dd), doublet of doublet of doublet 
(ddd), triplet (t), multiplet (m), quadruplet (q), tertiary carbons (C tert), quaternary carbons (C quat)). 
HRMS (FAB+) were determined on a high resolution Fisons Autospec-Q spectrometer at CESAMO 
(Talence, France). Chromatographic purifications were performed by flash silica gel Geduran SI 60 
(Merck) 0.040–0.063 mm column chromatography. 
5.1.1. 7,10-Dichloro-8-(4-O-methyl-1-deoxy-2,6-di-O-tosyl-β-d-glucopyranos-1-yl)-8,9-dihydro-1H-
indolo[2,3-a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione (13) 
To a solution of rebeccamycin (100 mg, 0.175 mmol) in THF (34 mL) were added K2CO3 (121 mg, 
0.877 mmol, 5 equiv.) and p-tosyl chloride (167 mg, 0.877 mmol, 5 equiv.). The mixture was refluxed for 
4 days. After removal of the solvent, the residue was purified by two successive flash chromatography on 
silica gel (eluents, cyclohexane/EtOAc, 8:2 and dichloromethane/EtOAc, 97.5:2.5) to give 13 (54.1 mg, 
0.062 mmol, 35% yield) as a yellow solid. Mp 140–143 °C. IR (KBr) 1715, 1760 cm−1, 
3300–3600 cm−1. HRMS (FAB+) (M)+ calcd for C41H33N3O11S2Cl2, 877.0934; found 877.1060. 1H NMR 
(400 MHz, DMSO-d6): 1.68 (3H, s, CH3), 2.23 (3H, s, CH3), 3.57 (3H, s, OCH3), 3.71 (1H, t, J = 8.5 Hz), 
4.10 (1H, q, J = 7.5 Hz), 4.49 (1H, ddd, J1 = 8.5 Hz, J2 = 6.5 Hz, J3 = 2.0 Hz), 4.58 (1H, dd, J1 = 11.5 Hz, 
J2 = 6.5 Hz), 4.72 (1H, dd, J1 = 11.5 Hz, J2 = 2.0 Hz), 4.91 (1H, dd, J1 = 9.0 Hz, J2 = 8.0 Hz), 6.28 (1H, d, 
J = 7.5 Hz), 6.56 (2H, d, J = 8.0 Hz), 6.66 (2H, d, J = 8.5 Hz), 6.75 (2H, d, J = 8.0 Hz), 7.37–7.42 (4H, 
m), 7.52 (1H, t, J = 8.0 Hz), 7.61 (1H, dd, J1 = 8.0 Hz, J2 = 1.0 Hz), 7.77 (1H, dd, J1 = 8.0 Hz, 
J2 = 1.0 Hz), 9.10 (1H, dd, J1 = 8.0 Hz, J2 = 1.0 Hz), 9.12 (1H, d, J = 7.5 Hz), 9.81 (1H, s, NH), 11.49 
(1H, s, NH). 13C NMR (100 MHz, DMSO-d6): 20.4, 21.0 (CH3), 60.0 (OCH3), 69.1 (CH2), 73.5, 76.5, 
78.8, 80.0, 80.7 (C1′, C2′, C3′, C4′, C5′), 115.2, 116.4, 118.0, 119.1, 120.6, 122.9, 123.3, 124.9, 128.0, 
128.8, 131.9, 132.3, 135.3, 137.2, 144.1, 144.3 (C quat arom), 122.4, 122.6, 123.7, 124.3, 125.6 (2C), 
127.0 (3C), 129.1 (4C), 130.1 (C tert arom), 170.3, 170.4 (C O). 
5.1.2. 7,10-Dichloro-8,9-(4-O-methyl-6-azido-1,2,6-trideoxy-β-d-mannopyranos-1,2-diyl)-8,9-
dihydro-1H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione (14) 
A mixture of 13 (100 mg, 0.114 mmol) and NaN3 (148 mg, 20 equiv.) in DMF (3 mL) was heated at 
70 °C for 1 week. Water was added. After extraction with EtOAc, the organic phase was washed with 
water and dried over MgSO4, the solvent was removed and the residue purified by flash chromatography 
(eluent, THF/dichloromethane, 2.5:97.5 then 5:95). After evaporation of the solvents, the solid was 
washed with diethylether to give 14 (34.9 mg, 0.060 mmol, 53% yield) as a yellow solid. Mp > 240 °C 
(decomposition). IR (KBr) 1710, 1750 cm−1, 2105 cm−1, 3300–3600 cm−1. HRMS 
(FAB+) (M + H)+ calcd for C27H18N6O5Cl2, 576.0716; found 576.0721. 1H NMR (400 MHz, DMSO-d6): 
3.38 (1H, m), 3.48 (3H, s, OCH3), 3.47 (1H, dd, J1 = 13.5 Hz, J2 = 7.5 Hz), 3.64 (1H, dd, J1 = 13.5 Hz, 
J2 = 3.5 Hz), 4.04 (1H, m), 4.64 (1H, m), 4.96 (1H, d, J = 6.5 Hz), 5.96 (1H, dd, J1 = 6.5 Hz, J2 = 3.0 Hz), 
6.91 (1H, d, J = 7.0 Hz), 7.44 (1H, t, J = 8.0 Hz), 7.47 (1H, t, J = 8.0 Hz), 7.66 (1H, dd, J1 = 8.0 Hz, 
J2 = 1.0 Hz), 7.70 (1H, dd, J1 = 8.0 Hz, J2 = 1.0 Hz), 8.67 (1H, d, J = 8.0 Hz), 8.72 (1H, d, J = 8.0 Hz), 
11.15 (1H, s, NH). 13C NMR (100 MHz, DMSO-d6): 52.8 (CH2), 56.4, 57.2, 68.6, 75.2, 79.5, 80.7 
(OCH3, C1′, C2′, C3′, C4′, C5′), 111.1 (2C), 116.6, 117.6, 120.3, 121.0, 126.0, 126.6, 128.1, 130.0, 136.1, 
136.8 (C quat arom), 122.3, 122.7, 122.9, 123.5, 127.7, 127.9 (C tert arom), 170.3 (2 C O). 
5.1.3. 8,9-(4-O-Methyl-6-amino-1,2,6-trideoxy-β-d-mannopyranos-1,2-diyl)-8,9-dihydro-1H-
indolo[2,3-a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione hydrochloride (1) 
A light-protected mixture of 14 (216 mg, 0.374 mmol), 10% Pd/C (648 mg) and HCOONH4 (648 mg) in 
methanol (53 mL) was stirred under argon atmosphere at room temperature for 4 days. After filtration 
over Celite, the solid residue was washed with EtOAc and methanol. The filtrate was evaporated and the 
residue dissolved in EtOAc. The organic phase was washed with saturated aqueous NaHCO3 and brine, 
and then was acidified with 1 N HCl. The aqueous phase was washed with EtOAc and treated with 
saturated aqueous NaHCO3. After extraction with EtOAc, the organic phase was dried over MgSO4. The 
solvent was removed, the residue dissolved into methanol and 1 N HCl (500 µL) was added before 
evaporation. Dichloromethane was added to the residue. Filtration gave compound 1 (69 mg, 0.133 mmol, 
36% yield). For spectroscopic data of compound 1 see Ref. [14]. 
5.2. Chk1 inhibitory assays 
Human Chk1 full-length enzyme with an N-terminal GST sequence was either purchased from Upstate 
Biochemicals (no. 14-346) or purified from extracts of Sf9 cells infected with a baculovirus encoding 
GST-Chk1. Assays for compound testing were based upon the method described by Davies et al. [18]. 
5.3. Src inhibition assays 
The drug was diluted with a Tecan Evo150 robot. The kinase assay was performed with 4 µL of inhibitor 
(10% dimethylsulfoxide, DMSO), 10 µL of kinase assay buffer 4× concentrated (80 mM MgCl2, 200 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 0.4 mM ethylenediamine-tetraacetic acid 
(EDTA), 2 mM dl-dithiothreitol (DTT)), 10 µL of substrate peptide (KVEKIGEGYYGVVYK, 370 nM) 
and 6 µL of Src kinase (stock GTP purified diluted with 1× kinase assay buffer to 200 nM). 10 µL of co-
substrate (40 µM ATP with 0.2 µCi P33-γ-ATP) was added with a Precision 2000 (Biotek Robotic). The 
assay was incubated for 20 min at 30 °C, stopped by adding 200 µL of 0.85% orthophosphoric acid, and 
then transferred to a phosphocellulose filter microplate (Whatman – P81). The plate was washed three 
times with 200 µL of 0.85% orthophosphoric acid and dried with 200 µL of acetone. The remaining 
activity was measured on a Topcount with 25 µL of scintillation solution (Packard UltimaGold). 
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